NovAccess Global（XSNX）株式概要バイオ医薬品会社であるノブアクセス・グローバル社は、米国で脳腫瘍患者を治療するための新規免疫療法を開発している。 詳細XSNX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析意味のある時価総額がありません ( $6K )株式の流動性は非常に低い 財務データは報告されていない すべてのリスクチェックを見るXSNX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0001該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m2m2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesNovAccess Global Inc. 競合他社AditxtSymbol: NasdaqCM:ADTXMarket cap: US$40.9kVincerx PharmaSymbol: OTCPK:VINCMarket cap: US$66.5kSynairgenSymbol: OTCPK:SYGG.FMarket cap: US$110.3kLipella PharmaceuticalsSymbol: OTCPK:LIPOMarket cap: US$646.5k価格と性能株価の高値、安値、推移の概要NovAccess Global過去の株価現在の株価US$0.000152週高値US$0.0552週安値US$0.000001ベータ01ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Mar 02NovAccess Global Inc., Annual General Meeting, May 06, 2024NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time.お知らせ • Feb 29NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLCNovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024.お知らせ • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 11NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.お知らせ • Jun 02NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare TherapiesNovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.お知らせ • Dec 30NovAccess Global Inc. announced delayed annual 10-K filingOn 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Mar 02NovAccess Global Inc., Annual General Meeting, May 06, 2024NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time.お知らせ • Feb 29NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLCNovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024.お知らせ • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 11NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.お知らせ • Jun 02NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare TherapiesNovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.お知らせ • Dec 30NovAccess Global Inc. announced delayed annual 10-K filingOn 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 11Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics for several years. With the addition of Dr. Weinstein, the NovAccess Global Scientific Advisory Board has five members, with disciplines spanning biotechnology and medical technology IP, healthcare IT, U.S. government agency and grant submissions, oncology drug development, and clinical research. Peter D. Weinstein, Ph.D., J.D counsels in all aspects of intellectual property, transaction and corporate law. He is the founder and Chief Executive Officer of Entralta, an intellectual property management company driven to bring the high quality of work to its clients by focusing on each client's needs. In addition, he is the chief legal counsel to NovAccess Global subsidiary StemVax Therapeutics. Dr. Weinstein received his Juris Doctorate degree at Boston College Law School, and is registered patent attorney licensed to practice law in California and Texas and is admitted to U.S. District Courts located in California and Texas. He also received a Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and worked on vaccine development. Prior to forming Entralta, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter's major hemophilia products like Advate® and major research and development programs in hemophilia that led to the approval by the FDA of Adenovate® and VonVendi®. This work entailed working with multidisciplinary teams in the United States, Europe, and Asia. Earlier, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was responsible for the Animal Health Group developing vaccines and other therapeutics for the treatment of infectious disease in large animals.お知らせ • Nov 10NovAccess Global Inc., Annual General Meeting, Nov 21, 2022NovAccess Global Inc., Annual General Meeting, Nov 21, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider and review the customary shareholder voting procedures and an investor presentation to be provided by the Company's management; and to discuss any other matters.お知らせ • Oct 27NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1NovAccess Global Inc. announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Glioblastoma is a form of aggressive brain cancer that annually impacts approximately 250,000 people globally and is on the rise in many countries, according to NovAccess scientists and published reports. The market data is more alarming, with glioblastoma accounting for approximately 50% of all malignant brain cancers diagnosed in the United States each year, and more than 10,000 Americans dying from this tumor type annually. Less than 5% of people with this cancer live longer than five years after their diagnosis. The global glioblastoma treatment market was estimated to be valued in excess of $2 billion in 2020, with projections for a compounded annual growth rate of more than 8% throughout the remainder of the decade. The FDA's Office of Orphan Products Development grants orphan designation status to investigational drugs and therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation provides benefits to drug developers which may include assistance in the drug development process, financial incentives to support clinical development, tax credits for clinical costs, exemptions from certain FDA fees and the potential for seven years of post-approval marketing exclusivity. Sponsors seeking orphan drug designation for a drug must submit a request for designation to the FDA. Orphan drug designation is a separate process from seeking commercial approval or licensing, and the receipt of orphan drug designation status does not change the regulatory requirements or process for obtaining marketing approval from the FDA.お知らせ • Aug 10NovAccess Global Inc. announced that it expects to receive $0.1 million in fundingNovAccess Global Inc. announced that it issued a convertible promissory note for gross proceeds of $100,000 to Nyla Sakakura-Clark on August 8, 2022. The note bears interest at the rate of 12% per year and is due on August 8, 2023.お知らせ • May 12NovAccess Global Inc. announced that it has received $0.9 million in funding from AJB Capital Investments LLCOn May 9, 2022, NovAccess Global Inc. closed the transaction.お知らせ • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 03NovAccess Global Inc. Announces Board ChangesOn January 31, 2022, NovAccess Global Inc. (‘NovAccess’) entered into a preferred stock redemption agreement (‘Agreement’) with TN3, LLC (‘TN3’), Mr. Daniel G. Martin, Irvin Consulting, LLC (‘IC’), and Dr. Dwain Morris-Irvin. Mr. Martin is the company's chairman of the board and owns TN3. Dr. Irvin is the company's chief executive officer and owns IC. Upon completion of the redemption, Mr. Martin will resign from the NovAccess board and be replaced by Dr. Irvin and John Cassarini.お知らせ • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 19NovAccess Global Inc. announced delayed 10-Q filingOn 05/18/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2020, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 29Novaccess Global Inc. Announces Executive ChangesNovAccess Global Inc. announced that L. Michael Yukich joined as fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors. Mike Yukich, age 74, has extensive financial and accounting experience and for the past twenty years he has held the position of chief financial officer for both public and private companies. Mr. Yukich currently serves as interim chief financial officer for Innovest Global Inc. Mr. Yukich served as Innovest’s CFO from August 2017 to October 2019 and rejoined the company in September 2020.お知らせ • Oct 16NovAccess Global Inc. Appoints Dr. Dwain Irvin as CEONovAccess Global Inc. announced the addition of Dr. Dwain Irvin as CEO. Dr. Irvin steps into the role after heading the Biotechnology division for Innovest Global Inc. Dr. Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.お知らせ • Aug 18XsunX, Inc. announced delayed 10-Q filingOn 08/17/2020, XsunX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.株主還元XSNXUS BiotechsUS 市場7D0%1.2%1.0%1Yn/a34.9%28.7%株主還元を見る業界別リターン: XSNXがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: XSNX US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is XSNX's price volatile compared to industry and market?XSNX volatilityXSNX Average Weekly Movementn/aBiotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: XSNXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のXSNXのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19972Dwain Morris-Irvinwww.novaccessglobal.comバイオ医薬品会社であるノブアクセス・グローバル社は、米国で脳腫瘍患者を治療するための新規免疫療法を開発している。癌を攻撃するために患者の免疫システムを利用することに関連した最先端の研究を専門としている。同社は1997年に設立され、オハイオ州チャグリンフォールズに本社を置いている。もっと見るNovAccess Global Inc. 基礎のまとめNovAccess Global の収益と売上を時価総額と比較するとどうか。XSNX 基礎統計学時価総額US$6.17k収益（TTM）-US$2.66m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率XSNX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計XSNX 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$2.66m収益-US$2.66m直近の収益報告Sep 30, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%XSNX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 12:07終値2026/05/18 00:00収益2024/09/30年間収益2024/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NovAccess Global Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 02NovAccess Global Inc., Annual General Meeting, May 06, 2024NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time.
お知らせ • Feb 29NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLCNovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024.
お知らせ • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 11NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
お知らせ • Jun 02NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare TherapiesNovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.
お知らせ • Dec 30NovAccess Global Inc. announced delayed annual 10-K filingOn 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 02NovAccess Global Inc., Annual General Meeting, May 06, 2024NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time.
お知らせ • Feb 29NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLCNovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024.
お知らせ • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 11NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
お知らせ • Jun 02NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare TherapiesNovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.
お知らせ • Dec 30NovAccess Global Inc. announced delayed annual 10-K filingOn 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 11Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics for several years. With the addition of Dr. Weinstein, the NovAccess Global Scientific Advisory Board has five members, with disciplines spanning biotechnology and medical technology IP, healthcare IT, U.S. government agency and grant submissions, oncology drug development, and clinical research. Peter D. Weinstein, Ph.D., J.D counsels in all aspects of intellectual property, transaction and corporate law. He is the founder and Chief Executive Officer of Entralta, an intellectual property management company driven to bring the high quality of work to its clients by focusing on each client's needs. In addition, he is the chief legal counsel to NovAccess Global subsidiary StemVax Therapeutics. Dr. Weinstein received his Juris Doctorate degree at Boston College Law School, and is registered patent attorney licensed to practice law in California and Texas and is admitted to U.S. District Courts located in California and Texas. He also received a Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and worked on vaccine development. Prior to forming Entralta, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter's major hemophilia products like Advate® and major research and development programs in hemophilia that led to the approval by the FDA of Adenovate® and VonVendi®. This work entailed working with multidisciplinary teams in the United States, Europe, and Asia. Earlier, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was responsible for the Animal Health Group developing vaccines and other therapeutics for the treatment of infectious disease in large animals.
お知らせ • Nov 10NovAccess Global Inc., Annual General Meeting, Nov 21, 2022NovAccess Global Inc., Annual General Meeting, Nov 21, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider and review the customary shareholder voting procedures and an investor presentation to be provided by the Company's management; and to discuss any other matters.
お知らせ • Oct 27NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1NovAccess Global Inc. announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Glioblastoma is a form of aggressive brain cancer that annually impacts approximately 250,000 people globally and is on the rise in many countries, according to NovAccess scientists and published reports. The market data is more alarming, with glioblastoma accounting for approximately 50% of all malignant brain cancers diagnosed in the United States each year, and more than 10,000 Americans dying from this tumor type annually. Less than 5% of people with this cancer live longer than five years after their diagnosis. The global glioblastoma treatment market was estimated to be valued in excess of $2 billion in 2020, with projections for a compounded annual growth rate of more than 8% throughout the remainder of the decade. The FDA's Office of Orphan Products Development grants orphan designation status to investigational drugs and therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation provides benefits to drug developers which may include assistance in the drug development process, financial incentives to support clinical development, tax credits for clinical costs, exemptions from certain FDA fees and the potential for seven years of post-approval marketing exclusivity. Sponsors seeking orphan drug designation for a drug must submit a request for designation to the FDA. Orphan drug designation is a separate process from seeking commercial approval or licensing, and the receipt of orphan drug designation status does not change the regulatory requirements or process for obtaining marketing approval from the FDA.
お知らせ • Aug 10NovAccess Global Inc. announced that it expects to receive $0.1 million in fundingNovAccess Global Inc. announced that it issued a convertible promissory note for gross proceeds of $100,000 to Nyla Sakakura-Clark on August 8, 2022. The note bears interest at the rate of 12% per year and is due on August 8, 2023.
お知らせ • May 12NovAccess Global Inc. announced that it has received $0.9 million in funding from AJB Capital Investments LLCOn May 9, 2022, NovAccess Global Inc. closed the transaction.
お知らせ • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 03NovAccess Global Inc. Announces Board ChangesOn January 31, 2022, NovAccess Global Inc. (‘NovAccess’) entered into a preferred stock redemption agreement (‘Agreement’) with TN3, LLC (‘TN3’), Mr. Daniel G. Martin, Irvin Consulting, LLC (‘IC’), and Dr. Dwain Morris-Irvin. Mr. Martin is the company's chairman of the board and owns TN3. Dr. Irvin is the company's chief executive officer and owns IC. Upon completion of the redemption, Mr. Martin will resign from the NovAccess board and be replaced by Dr. Irvin and John Cassarini.
お知らせ • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 19NovAccess Global Inc. announced delayed 10-Q filingOn 05/18/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2020, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 29Novaccess Global Inc. Announces Executive ChangesNovAccess Global Inc. announced that L. Michael Yukich joined as fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors. Mike Yukich, age 74, has extensive financial and accounting experience and for the past twenty years he has held the position of chief financial officer for both public and private companies. Mr. Yukich currently serves as interim chief financial officer for Innovest Global Inc. Mr. Yukich served as Innovest’s CFO from August 2017 to October 2019 and rejoined the company in September 2020.
お知らせ • Oct 16NovAccess Global Inc. Appoints Dr. Dwain Irvin as CEONovAccess Global Inc. announced the addition of Dr. Dwain Irvin as CEO. Dr. Irvin steps into the role after heading the Biotechnology division for Innovest Global Inc. Dr. Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.
お知らせ • Aug 18XsunX, Inc. announced delayed 10-Q filingOn 08/17/2020, XsunX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
